# PeptideScanner evidence objects: MK-677

Every published version of the records placed with MK-677, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/mk-677.json. Selected public evidence only; not medical advice.

- Objects: 6
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00395291-mk-677-v1"></a>

## ClinicalTrials.gov record NCT00395291

> PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.

- Evidence object: `story:clinicaltrials-gov-nct00395291-mk-677:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00395291-mk-677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/mk-677.json#clinicaltrials-gov-nct00395291-mk-677-v1
- Content SHA-256: `5430a35eec591b530e8453a25e6edc3d86eb840f032fad15ce8e0ef2763f57cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00395291 ([`ctg-observation-nct00395291-2017-02-20-7eddc98e3167`](#source-ctg-observation-nct00395291-2017-02-20-7eddc98e3167))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677. ([`ctg-observation-nct00395291-2017-02-20-7eddc98e3167`](#source-ctg-observation-nct00395291-2017-02-20-7eddc98e3167))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677. ([`ctg-observation-nct00395291-2017-02-20-7eddc98e3167`](#source-ctg-observation-nct00395291-2017-02-20-7eddc98e3167))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00395291-2017-02-20-7eddc98e3167`](#source-ctg-observation-nct00395291-2017-02-20-7eddc98e3167))

### Sources

<a id="source-ctg-observation-nct00395291-2017-02-20-7eddc98e3167"></a>
- **ClinicalTrials.gov record NCT00395291 · retained source version 2017-02-20:7eddc98e31675d85380fcc95ab40afc3ee2831e37a2fc64dad3ee3069547e5e9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00395291) (`ctg-observation-nct00395291-2017-02-20-7eddc98e3167`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00395291." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/mk-677.json#clinicaltrials-gov-nct00395291-mk-677-v1 SHA-256: 5430a35eec591b530e8453a25e6edc3d86eb840f032fad15ce8e0ef2763f57cf.

---

<a id="clinicaltrials-gov-nct05364684-mk-677-v1"></a>

## ClinicalTrials.gov record NCT05364684

> PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677.

- Evidence object: `story:clinicaltrials-gov-nct05364684-mk-677:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05364684-mk-677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/mk-677.json#clinicaltrials-gov-nct05364684-mk-677-v1
- Content SHA-256: `65dd72e3ba14756ba87237b2fadd08c480353c4f76b822c335a9f4637fbe4374`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05364684 ([`ctg-observation-nct05364684-2026-01-06-6a1c03e1905a`](#source-ctg-observation-nct05364684-2026-01-06-6a1c03e1905a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677. ([`ctg-observation-nct05364684-2026-01-06-6a1c03e1905a`](#source-ctg-observation-nct05364684-2026-01-06-6a1c03e1905a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677. ([`ctg-observation-nct05364684-2026-01-06-6a1c03e1905a`](#source-ctg-observation-nct05364684-2026-01-06-6a1c03e1905a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05364684-2026-01-06-6a1c03e1905a`](#source-ctg-observation-nct05364684-2026-01-06-6a1c03e1905a))

### Sources

<a id="source-ctg-observation-nct05364684-2026-01-06-6a1c03e1905a"></a>
- **ClinicalTrials.gov record NCT05364684 · retained source version 2026-01-06:6a1c03e1905a489d737d77514f8dfbd8449021b6781afdbd2864a9b5a02a411c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05364684) (`ctg-observation-nct05364684-2026-01-06-6a1c03e1905a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05364684." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/mk-677.json#clinicaltrials-gov-nct05364684-mk-677-v1 SHA-256: 65dd72e3ba14756ba87237b2fadd08c480353c4f76b822c335a9f4637fbe4374.

---

<a id="pubmed-pmid-31964466-mk-677-v1"></a>

## Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles.

> PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31964466-mk-677:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31964466-mk-677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-31964466-mk-677-v1
- Content SHA-256: `afd25a669f67e4a3ac42d283f6130672937fc0c8ec4f12d3b2db45943acf8feb`

### Claims and source pins

#### Headline

Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. ([`pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef`](#source-pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef))

#### Summary

PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef`](#source-pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef))

#### Paragraph 1

PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef`](#source-pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef`](#source-pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef))

### Sources

<a id="source-pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef"></a>
- **Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. · retained source version 1:2020-11-16:current:b6841e2283efc507f2af7da1e32e82018c68b93d0aef64af4db30c20e4fbfd00** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31964466/) (`pubmed-observation-pmid-31964466-2020-11-16-b6841e2283ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-31964466-mk-677-v1 SHA-256: afd25a669f67e4a3ac42d283f6130672937fc0c8ec4f12d3b2db45943acf8feb.

---

<a id="pubmed-pmid-34542924-mk-677-v1"></a>

## Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.

> PubMed lists PMID 34542924 in Rapid communications in mass spectrometry : RCM as Journal Article, with publication-date metadata of 2021-12-15 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34542924-mk-677:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-01-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34542924-mk-677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-34542924-mk-677-v1
- Content SHA-256: `50d3190eb81f2f4d9e398686c40467ae9ed415808e6bda7403cefeefd05eea20`

### Claims and source pins

#### Headline

Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren. ([`pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5`](#source-pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5))

#### Summary

PubMed lists PMID 34542924 in Rapid communications in mass spectrometry : RCM as Journal Article, with publication-date metadata of 2021-12-15 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5`](#source-pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5))

#### Paragraph 1

PubMed lists PMID 34542924 in Rapid communications in mass spectrometry : RCM as Journal Article, with publication-date metadata of 2021-12-15 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5`](#source-pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5`](#source-pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5))

### Sources

<a id="source-pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5"></a>
- **Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren. · retained source version 1:2022-01-31:current:f12b83f64da5e2a95a794ac6ceb51beb07308d2bc9c2a6c8615cfae800e9ff68** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34542924/) (`pubmed-observation-pmid-34542924-2022-01-31-f12b83f64da5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-34542924-mk-677-v1 SHA-256: 50d3190eb81f2f4d9e398686c40467ae9ed415808e6bda7403cefeefd05eea20.

---

<a id="pubmed-pmid-34737341-mk-677-v1"></a>

## Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.

> PubMed lists PMID 34737341 in Nature communications as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-04 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34737341-mk-677:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34737341-mk-677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-34737341-mk-677-v1
- Content SHA-256: `2abe96751bf94604787d471f3c16be564a677cd5c0d0121ffc1fdee831cb1658`

### Claims and source pins

#### Headline

Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. ([`pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6`](#source-pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6))

#### Summary

PubMed lists PMID 34737341 in Nature communications as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-04 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6`](#source-pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6))

#### Paragraph 1

PubMed lists PMID 34737341 in Nature communications as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-04 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6`](#source-pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6`](#source-pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6))

### Sources

<a id="source-pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6"></a>
- **Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. · retained source version 1:2022-10-20:current:266ec2e956f602a3cf5441e73d0b374daf715a5931522f50dd222d825d7a8193** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34737341/) (`pubmed-observation-pmid-34737341-2022-10-20-266ec2e956f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-34737341-mk-677-v1 SHA-256: 2abe96751bf94604787d471f3c16be564a677cd5c0d0121ffc1fdee831cb1658.

---

<a id="pubmed-pmid-36303408-mk-677-v1"></a>

## LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.

> PubMed lists PMID 36303408 in Experimental physiology as Case Reports, Research Support, Non-U.S. Gov't, Journal Article, with publication-date metadata of 2022-11-16 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36303408-mk-677:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36303408-mk-677/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-36303408-mk-677-v1
- Content SHA-256: `0066b10306820b3ac745df38816e999727dca69a9076f5e045edbf2bc15f6779`

### Claims and source pins

#### Headline

LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. ([`pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40`](#source-pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40))

#### Summary

PubMed lists PMID 36303408 in Experimental physiology as Case Reports, Research Support, Non-U.S. Gov't, Journal Article, with publication-date metadata of 2022-11-16 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40`](#source-pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40))

#### Paragraph 1

PubMed lists PMID 36303408 in Experimental physiology as Case Reports, Research Support, Non-U.S. Gov't, Journal Article, with publication-date metadata of 2022-11-16 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40`](#source-pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40`](#source-pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40))

### Sources

<a id="source-pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40"></a>
- **LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. · retained source version 1:2026-01-27:current:4bdf8b698c40396ed3ccb1d4e186d7e161a0102c4dc9e10a4e3a4e39377e3861** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36303408/) (`pubmed-observation-pmid-36303408-2026-01-27-4bdf8b698c40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/mk-677.json#pubmed-pmid-36303408-mk-677-v1 SHA-256: 0066b10306820b3ac745df38816e999727dca69a9076f5e045edbf2bc15f6779.

